Narcotic-Free Percutaneous Nephrolithotomy
Nephrolithiasis
About this trial
This is an interventional treatment trial for Nephrolithiasis
Eligibility Criteria
Inclusion Criteria: Undergoing scheduled unilateral standard (24Fr), PCNL with at least 2cm stone burden, with expected single access Exclusion Criteria: Pregnant women History of chronic opioid abuse Allergy, hypersensitivity, or other contraindication to NSAID usage such as eGFR < 60 mL/min Peptic ulcer disease or history of gastric bypass Concurrent use of antiplatelet or anticoagulation therapy (including aspirin) Thrombocytopenia Suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis, and those at high risk of bleeding. Concomitant medications: Other NSAIDs Antiplatelet or anticoagulation medications Probenecid Pentoxifylline Allergy, hypersensitivity, or other contraindication to opioids: Current opioid prescription/usage for any reason, including active treatment with suboxone or methadone Respiratory depression Patients with acute or severe bronchial asthma or hypercarbia Patients who have or is suspected of having paralytic ileus as PCNL done under general anesthesia Patients with hepatic Impairment Concomitant medications: Monoamine Oxidase Inhibitors (MAOIs) Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics Diagnosis of chronic pain disorder Reduced sensation of abdomen or pelvis (e.g. patients with spinal cord injury) Pre-existing stent or nephrostomy tube Urinary tract anomalies such as urinary diversion, horseshoe kidney, solitary kidney, urinary stricture disease, ureteropelvic junction obstruction, pelvic kidney, stone in calyceal diverticulum) Pulmonary disease Liver disease Seizure disorders Subjects taking nephrotoxic medications Subjects taking medications that can increase sedation risk (benzodiazepines or other sedative hypnotics)
Sites / Locations
- Mount Sinai WestRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Opioid group
NSAID
Patients will be prescribed 5mg Oxycodone, Q6 PRN postoperatively.
Patients will be prescribed 10mg Ketorolac, Q6 PRN postoperatively.